NASDAQ:RGEN - Repligen Stock Price, Forecast & News

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.19 by $0.07. The biotechnology company had revenue of $69.45 million for the quarter, compared to analysts' expectations of $66.10 million. Repligen had a net margin of 9.28% and a return on equity of 6.50%. The business's revenue was up 40.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.20 EPS. View Repligen's Earnings History.

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Repligen.

Repligen updated its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share guidance of $1.00-1.04 for the period, compared to the Thomson Reuters consensus estimate of $0.97. The company issued revenue guidance of $267-270 million, compared to the consensus revenue estimate of $266.06 million.

7 equities research analysts have issued 12-month price objectives for Repligen's stock. Their forecasts range from $100.00 to $110.00. On average, they expect Repligen's share price to reach $106.14 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for Repligen.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.

Headlines about RGEN stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Repligen earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View News Stories for Repligen.

Repligen saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 2,420,000 shares, a decline of 29.4% from the December 15th total of 3,430,000 shares. Based on an average daily trading volume, of 397,600 shares, the short-interest ratio is currently 6.1 days. Currently, 5.1% of the company's shares are sold short. View Repligen's Current Options Chain.

Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Veeva Systems (VEEV), Xilinx (XLNX), salesforce.com (CRM), Corcept Therapeutics (CORT), Micron Technology (MU), Fortinet (FTNT) and Okta (OKTA).

Repligen's stock is owned by many different of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (0.16%), Assenagon Asset Management S.A. (0.02%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.01%), NewSquare Capital LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

RGEN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Summit Creek Advisors LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes and Ralf Kuriyel. View Insider Buying and Selling for Repligen.

RGEN stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., NewSquare Capital LLC, Janney Montgomery Scott LLC, Ballentine Partners LLC, Allred Capital Management LLC, Zurcher Kantonalbank Zurich Cantonalbank , Lenox Wealth Advisors LLC and Louisiana State Employees Retirement System. View Insider Buying and Selling for Repligen.

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RGEN stock can currently be purchased for approximately $100.85.

Repligen has a market capitalization of $5.25 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen.

The official website for Repligen is http://www.repligen.com/.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected]